France

Efficacy and safety of GSK4527226 in participants with early Alzheimer's disease

Long term, extension study of the safety and efficacy of AVP-786 for the treatment of agitation in patients with dementia of the Alzheimer's type

Masitinib in patients with mild to moderate Alzheimer's disease

A study to assess efficacy and safety of KarXT for the treatment of psychosis associated with Alzheimer's disease dementia

A Phase 3, multicenter, randomised, double-blind, placebo-controlled study of the efficacy, safety and biomarker effects of ALZ-801 in subjects with early Alzheimer's disease and APOE4/4 genotype

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

Effect of caffeine on cognition in Alzheimer's disease

A randomised, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of BIIB080 in subjects with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia

Donepezil versus non-drug treatment in Alzheimer's disease

A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease

A study of potential disease modifying treatments in individuals at risk for or with a type of early onset Alzheimer’s disease caused by a genetic mutation (DIAN-TU)

A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL593 in healthy participants and participants with Frontotemporal Dementia (FTD-GRN)

A study to evaluate safety and tolerability of aducanumab in participants with Alzheimer's disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205

A study to verify the clinical benefit of Aducanumab in participants with early Alzheimer's disease

evoke - A research study investigating Semaglutide in people with early Alzheimer's disease

evoke+ - A research study investigating Semaglutide in people with early Alzheimer's disease

A clinical trial to look at how well RO7269162 works in people who are at risk of Alzheimer’s disease or who have mild cognitive impairment due to Alzheimer’s disease and how safe RO7269162 is at different doses

Therapeutic evaluation of low-dose IL-2-based immunomodulatory approach in patients with early Alzheimer's disease

A Phase 3 study to evaluate efficacy and safety of AL001 in frontotemporal dementia

A Phase 2 study to evaluate efficacy and safety of AL002 in rarticipants with early Alzheimer's disease

A prospective, multicenter, with a first randomised, placebo-controlled, parallel-group, double-blind period followed by an open-label trial period to evaluate the clinical safety and efficacy of NanoLithium® NP03 in patients with mild-to-severe Alzheimer’s disease: a proof-of-concept study

Phase 3, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of AR1001 in participants with early Alzheimer's disease

A study to test the efficacy, safety, and tolerability of bepranemab in patients with mild cognitive impairment or mild Alzheimer's disease

A Phase 2a study of TPN-101 in patients with C9ORF72 ALS/FTD